NIPTE Receives FDA Contract to Develop Program in State-of-the-Art Pharmaceutical Manufacturing Science for Reviewers

NIPTE Receives FDA Contract to Develop Educational Program in State-of-the-Art Pharmaceutical Manufacturing Science for FDA Reviewers

WEST LAFAYETTE, Ind. - (Business Wire) The U.S. Food and Drug Administration (FDA) has awarded the National Institute for Pharmaceutical Technology and Education, Inc. (NIPTE) a $652,000 two-year contract to develop and deliver a professional development program to help to ensure that FDA reviewers are current in state-of-the-art pharmaceutical manufacturing and technology.

The implementation of this contract will require the design, development, delivery and assessment of a well-structured educational program based on the needs of the FDA's Office of Pharmaceutical Science (OPS) staff that review and evaluate the quality information for new drug applications. The program will increase the ability of reviewers to apply the newly acquired knowledge to practical issues associated with the review, research and policy-making activities. "As educators, we are very pleased to have this opportunity to work with the FDA. We believe that this project will help facilitate the incorporation of advanced technologies into pharmaceutical manufacturing," said Lee Kirsch, professor of pharmaceutics at the University of Iowa and NIPTE faculty member who will serve as the project manager on this contract.

In the initial period, NIPTE will work with the OPS on identifying the needs and developing recommendations on training areas. Once the assessment is complete, NIPTE will develop and deliver a scientific training program for the designated OPS staff. "NIPTE has two interconnected goals which are advancing research and education. This project fits very well with our mission," said Prabir Basu, executive director of NIPTE.

The program will begin this year and is expected to be completed by September 2011.

ABOUT NIPTE

The National Institute of Pharmaceutical Technology and Education (NIPTE) is an independent, non-profit organization representing 11 U.S. universities that are leaders in pharmaceutical science and engineering. The member universities are Duquesne University, Illinois Institute of Technology, Purdue University, Rutgers University, University of Puerto Rico, University of Connecticut, University of Iowa, University of Kansas, University of Kentucky, University of Maryland - Baltimore, and the University of Minnesota. Visit NIPTE on the web at www.nipte.org.


NIPTE
Prabir K. Basu, 765-494-9614
[email protected]

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.